Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study

Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study

Background: Thymoma-associated myasthenia gravis (TAMG) is a subtype of myasthenia gravis (MG) that is associated with more severe symptoms and a relatively poor prognosis. Eculizumab, an inhibitor to target human C5 component of the complement cascade, is considered a treatment option for refractor...

Descrizione completa

Dettagli Bibliografici
Autori principali: Lei Jin, Dingxian He, Quantao Zeng, Song Tan, Jianquan Shi, Ying Liu, Zhangyu Zou, Jie Song, Chong Yan, Xiao Huan, Yuan Wang, Lei Yang, Jianying Xi, Zongtai Wu, Ziqi Liu, Jianming Zheng, Chongbo Zhao, Xianglin Chu, Sushan Luo
Natura: Articolo
Lingua:English
Pubblicazione: SAGE Publishing 2024-12-01
Serie:Therapeutic Advances in Neurological Disorders
Accesso online:https://doi.org/10.1177/17562864241309431

Accesso online

https://doi.org/10.1177/17562864241309431

Documenti analoghi